# US 2014/0154248 A1 · Recombinant immunotoxin targeting mesothelin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154248 A1
- Document ID: US20140154248A1
- Status: Published application
- Kind: A1
- Application number: 14/115,131
- Filed: 2012-05-04
- Published: 2014-06-05
- Earliest claimed: 2011-05-06
- Assignees: The United States of America as represented by the Secretary, Department of Health and Human Service
- Inventors: Ira H. Pastan; John Weldon; Richard Beers
- Web page: https://patentgrep.com/patent/US20140154248A1

## CPC

- C07K 16/30: from tumour cells
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001168: {Mesothelin [MSLN]}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/50: containing protease site
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

## Claims

### Claim 1

A chimeric molecule comprising a fusion polypeptide having the formula M-L1-FCS-FL-functional PE domain III, wherein
M is an antibody which specifically binds to mesothelin, or a fragment thereof that specifically binds mesothelin;
L1 consists of from 1 to 10 continuous amino acid residues;
FCS is a furin cleavage site consisting of continuous amino acid residues capable of being cleaved by furin;
FL consists of from 3 to 8 continuous amino acid residues selected independently from glycine and serine;
Functional PE domain III consists of continuous amino acid residues identical in sequence to SEQ ID NO:1 from position 395 to 613, optionally comprising (i) substitutions in one or more residues corresponding to 609-613 of SEQ ID NO:1, (ii) a substitution of glycine, alanine, valine, leucine, or isoleucine for arginine at a position corresponding to position 490 of SEQ ID NO:1, (iii) a substitution of one or more residues corresponding to residues of SEQ ID NO:1, which residues of SEQ ID NO:1 maintain immunogenicity of an epitope or subepitope of PE domain III, or (iv) a combination of any of (i)-(iii).

### Claim 2 (depends on 1)

The molecule of claim 1, wherein the antibody is a minibody, a diabody, a triabody, an Fab′ fragment, an F(ab)′2 fragment, a single chain Fv protein (“scFv”), or a disulfide stabilized Fv protein (“dsFv”) fragment.

### Claim 3 (depends on 1)

The molecule of claim 1, wherein the antibody fragment comprises disulfide stabilized light and heavy chain immunoglobulin variable regions fused to the remainder of the molecule through linkage of the heavy chain to L1.

### Claim 4 (depends on 1)

The molecule of claim 1, wherein the antibody comprises:
a VH chain comprising a CDR1 amino acid sequence of GYTMN (SEQ ID NO:51), a CDR2 amino acid sequence of LITPYNGASSYNQKFRG (SEQ ID NO:52), and a CDR3 amino acid sequence of GGYDGRGFDY (SEQ ID NO:53), and
a VL chain comprising a CDR1 amino acid sequence of SASSSVSYMH (SEQ ID NO:54), a CDR2 amino acid sequence of DTSKLAS (SEQ ID NO:55), and a CDR3 amino acid sequence selected from the group consisting of QQWSGYPLT (SEQ ID NO:56), QQWSKHPLT (SEQ ID NO:57), QQWSGHPLT (SEQ ID NO:58), QQWSAHPLT (SEQ ID NO:59), QQWSQIPLT (SEQ ID NO:60), QQWGFNPLT (SEQ ID NO:61), QQWGTNPLT (SEQ ID NO:62), QQWGSHPLT (SEQ ID NO:63), QQWGDFPLT (SEQ ID NO:64), QQWGDHPLT (SEQ ID NO:65), QQWSAHPLT (SEQ ID NO:66), and QQWSGYPTT (SEQ ID NO:67).

### Claim 5 (depends on 4)

The molecule of claim 4, wherein the VL CDR3 amino acid sequence is QQWSKHPLT (SEQ ID NO:57).

### Claim 6 (depends on 1)

The molecule of claim 1, wherein L1 is 3 to 5 amino acids in length.

### Claim 7 (depends on 1)

The molecule of claim 1, wherein L1 is ASGG (SEQ ID NO:19).

### Claim 8 (depends on 1)

The molecule of claim 1, wherein the PE domain III has a substitution of alanine, glycine or serine of at least one amino acid residue corresponding to an amino acid residue of SEQ ID NO:1 selected from the group consisting of D403, R412, R427, E431, R458, D461, R505, E522, R538, R551, R576 and L597.

### Claim 9 (depends on 1)

The molecule of claim 1, wherein the PE domain III has a substitution of alanine, glycine or serine of at least one amino acid residue corresponding to an amino acid residue of SEQ ID NO:1 selected from the group consisting of D406, R432, R467, R490, R513, E548, K590 and Q592.

### Claim 10 (depends on 1)

The molecule of claim 1, wherein the FL is GGS, (GGS)2 (SEQ ID NO:18), GSGG (SEQ ID NO:71), GGSGG (SEQ ID NO:72), GGSG (SEQ ID NO:73), GSG, or GGG.

### Claim 11 (depends on 1)

The molecule of claim 1, wherein FL is GGS.

### Claim 12 (depends on 1)

The molecule of claim 1, wherein the furin cleavage sequence is RHRQPRGWEQL (SEQ ID NO:17).

### Claim 13 (depends on 1)

The molecule of claim 1, wherein the PE functional Domain III is the PE functional domain Domain III of LR having the amino acid sequence of SEQ ID NO:4 from position 20 to 237 or of SEQ ID NO:5 from position 20 to 237.

### Claim 14 (depends on 1)

The molecule of claim 1, wherein the antibody comprises a disulfide stabilized SS1 variable light chain of SEQ ID NO: 6 and SS1 variable heavy chain of sequence of SEQ ID NO:7.

### Claim 15 (depends on 1)

The molecule of claim 1, wherein the molecule comprises the SS1 variable light chain of SEQ ID NO: 6 and the SS1 variable heavy chain-PE fusion polypeptide of SEQ ID NO:8 wherein the variable light and heavy chains form a disulfide stabilized antibody.

### Claim 16 (depends on 1)

The molecule of claim 1, wherein the FCS is identical in sequence to SEQ ID NO:1 from position 274 to 284 or of the amino acid sequence RHRSKRGWEQL (SEQ ID NO:29).

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the molecule of claim 1 and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A nucleic acid encoding the molecule of claim 1.

### Claim 19 (depends on 18)

A vector comprising the nucleic acid of claim 18.

### Claim 20 (depends on 18)

A host cell comprising the nucleic acid of claim 18.

### Claim 21 (depends on 1)

A method of treating a cancer which overexpresses mesothelin in a subject in need thereof, comprising administering the chimeric molecule of claim 1 to the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is a lung adenocarcinoma, an ovarian carcinoma, mesothelioma and/or epidermoid carcinoma.

### Claim 23

A fusion polypeptide having the formula FCS-FL-PE functional Domain III, wherein:
FCS consists of continuous amino acid residues identical in sequence to SEQ ID NO:1 from position 274 to 284 or of the amino acid sequence RHRSKRGWEQL (SEQ ID NO:17);
FL consists of from 3 to 8 continuous amino acid residues selected independently from glycine and serine;
PE functional domain III consists of continuous amino acid residues identical in sequence to SEQ ID NO:1 from position 395 to 613, optionally comprising (i) substitutions in one or more residues corresponding to 609-613 of SEQ ID NO:1, (ii) a substitution of glycine, alanine, valine, leucine, or isoleucine for arginine at a position corresponding to position 490 of SEQ ID NO:1, (iii) a substitution of one or more residues corresponding to residues of SEQ ID NO:1, which residues of SEQ ID NO:1 maintain immunogenicity of a epitope or subepitope of PE domain III, or (iv) a combination of any of (i)-(iii).

### Claim 24 (depends on 23)

A nucleic acid encoding the polypeptide of claim 23.
